Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott R Plotkin

Showing results (91-100 of 201) with videos related to

Pageof 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Treatment of relapsed central nervous system lymphoma with high-dose methotrexateScott R Plotkin, Rebecca A Betensky, Fred H Hochberg, et al.
Neurology|April 30, 2020
Correlation between NF1 genotype and imaging phenotype on whole-body MRI: NF1 radiogenomicsYunpeng Liu, Justin T Jordan, Miriam A Bredella, et al.
Cancer Research|April 22, 2010
Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumorsHon Kit Wong, Johanna Lahdenranta, Walid S Kamoun, et al.
Neurology|November 20, 2013
Achieving consensus for clinical trials: the REiNS International CollaborationScott R Plotkin, Jaishri O Blakeley, Eva Dombi, et al.
Neurology|November 20, 2013
Conclusions and future directions for the REiNS International CollaborationBrigitte C Widemann, Jaishri O Blakeley, Eva Dombi, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 24, 2022
COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosisJineta Banerjee, Jan M Friedman, Laura J Klesse, et al.
Orphanet Journal of Rare Diseases|February 1, 2021
The impact of the COVID-19 pandemic on neurofibromatosis clinical care and researchHeather B Radtke, Bonita P Klein-Tasman, Vanessa L Merker, et al.
American Journal of Medical Genetics. Part A|March 26, 2014
Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosisVanessa L Merker, Miriam A Bredella, Wenli Cai, et al.
The Oncologist|April 10, 2020
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of ToxicitiesLaura J Klesse, Justin T Jordan, Heather B Radtke, et al.
Neurology|November 20, 2013
Hearing and facial function outcomes for neurofibromatosis 2 clinical trialsScott R Plotkin, Simone L Ardern-Holmes, Fred G Barker, et al.
Pageof 21

Showing results (91-100 of 201) with videos related to

Sort By:
Pageof 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 10, 2004
Treatment of relapsed central nervous system lymphoma with high-dose methotrexateScott R Plotkin, Rebecca A Betensky, Fred H Hochberg, et al.
Neurology|April 30, 2020
Correlation between NF1 genotype and imaging phenotype on whole-body MRI: NF1 radiogenomicsYunpeng Liu, Justin T Jordan, Miriam A Bredella, et al.
Cancer Research|April 22, 2010
Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumorsHon Kit Wong, Johanna Lahdenranta, Walid S Kamoun, et al.
Neurology|November 20, 2013
Achieving consensus for clinical trials: the REiNS International CollaborationScott R Plotkin, Jaishri O Blakeley, Eva Dombi, et al.
Neurology|November 20, 2013
Conclusions and future directions for the REiNS International CollaborationBrigitte C Widemann, Jaishri O Blakeley, Eva Dombi, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|December 24, 2022
COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosisJineta Banerjee, Jan M Friedman, Laura J Klesse, et al.
Orphanet Journal of Rare Diseases|February 1, 2021
The impact of the COVID-19 pandemic on neurofibromatosis clinical care and researchHeather B Radtke, Bonita P Klein-Tasman, Vanessa L Merker, et al.
American Journal of Medical Genetics. Part A|March 26, 2014
Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosisVanessa L Merker, Miriam A Bredella, Wenli Cai, et al.
The Oncologist|April 10, 2020
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of ToxicitiesLaura J Klesse, Justin T Jordan, Heather B Radtke, et al.
Neurology|November 20, 2013
Hearing and facial function outcomes for neurofibromatosis 2 clinical trialsScott R Plotkin, Simone L Ardern-Holmes, Fred G Barker, et al.
Pageof 21